Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Uniqure stock

Learn how to easily invest in Uniqure stock.

Uniqure NV is a biotechnology business based in the US. Uniqure shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. Uniqure employs 463 staff and has a trailing 12-month revenue of around $62 million.

How to buy shares in Uniqure

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – QURE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Uniqure stock price (NASDAQ: QURE)

Use our graph to track the performance of QURE stocks over time.

Uniqure shares at a glance

Information last updated 2022-10-02.
Latest market close$19.53
52-week range$12.52 - $36.55
50-day moving average $20.58
200-day moving average $18.38
Wall St. target price$49.75
PE ratio 2.4684
Dividend yield $0 (0%)
Earnings per share (TTM) $7.60

Buy Uniqure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Uniqure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Uniqure price performance over time

Historical closes compared with the close of $19.53 from 2022-10-03

1 week (2022-09-28) 3.55%
1 month (2022-09-02) -5.47%
3 months (2022-07-05) -6.29%
6 months (2022-04-05) -0.41%
1 year (2021-10-05) -37.66%
2 years (2020-10-05) -48.44%
3 years (2019-10-04) 42.7
5 years (2017-10-05) 84.07%

Is Uniqure stock undervalued or overvalued?

Valuing Uniqure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Uniqure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Uniqure's P/E ratio

Uniqure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Uniqure shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Uniqure financials

Revenue TTM $62 million
Gross profit TTM $362.2 million
Return on assets TTM -12.28%
Return on equity TTM -20.37%
Profit margin -184.06%
Book value $10.42
Market capitalisation $876.6 million

TTM: trailing 12 months

Uniqure share dividends

We're not expecting Uniqure to pay a dividend over the next 12 months.

Have Uniqure's shares ever split?

Uniqure's shares were split on a 1:5 basis on 30 January 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Uniqure shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Uniqure shares which in turn could have impacted Uniqure's share price.

Uniqure share price volatility

Over the last 12 months, Uniqure's shares have ranged in value from as little as $12.52 up to $36.55. A popular way to gauge a stock's volatility is its "beta".

QURE.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Uniqure's is 1.0743. This would suggest that Uniqure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Uniqure overview

uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N. V.

Frequently asked questions

What percentage of Uniqure is owned by insiders or institutions?
Currently 7.018% of Uniqure shares are held by insiders and 97.757% by institutions.
How many people work for Uniqure?
Latest data suggests 463 work at Uniqure.
When does the fiscal year end for Uniqure?
Uniqure's fiscal year ends in December.
Where is Uniqure based?
Uniqure's address is: Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
What is Uniqure's ISIN number?
Uniqure's international securities identification number is: NL0010696654
What is Uniqure's CUSIP number?
Uniqure's Committee on Uniform Securities Identification Procedures number is: N90064101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site